icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
HunrKzm9KuUgYwWm
Listen
